European Leukemia Trial Registry
Trial: ALL GRAALLPHAG06/ EWALL-PH-01

More Details
Title Effectiveness and compatibility of a combination therapy of Dasatinib (trade name: Sprycel®) with Vincristin and Dexamethason with Philadelphia chromosome positive ALL
Scientific Title An open label phase II study to evaluate the efficacy and safety of induction and consolidation therapy with dasatinib in combination with chemotherapy in patients aged 55 years and over with Philadelphia chromosome positive (Ph+ or BCRABL+) acute lymphoblastic leukemia (ALL) EWALL-PH-01 (GRAALPHAG06)
Short Title ALL GRAALLPHAG06/ EWALL-PH-01
Trialgroup EWALL
Type of Trial multicentric, open-label
Disease Acute lymphoblastic leukemia(ALL) Ph/BCR ABL +
Age >=55 years
Status Closed
Start of Recruitment 15.07.2007
Leader Ottmann, Prof. Dr., Oliver
Contactperson

principal investigator
Ottmann, Prof. Dr., Oliver
Tel: +49 (0)69 6301 87070
Fax: +49 (0)69 6301 4170
Email: ottmann@em.uni-frankfurt.de

Study Centre
Gökbuget, Dr. med., Nicola
Tel: +49 (0)69 6301-6366
Fax: +49 (0)69 6301- 7463
Email: goekbuget@em.uni-frankfurt.de

Shortprotocol Shortprotocol
Diagnostics

Immunophaenotyping
Immunologisches Markerlabor der Charité Berlin, Campus Benjamin-Franklin

MRD-Analysis
Molekulargenetik-Labor der Med.Klinik II, Universitätsklinikum Frankfurt

created 04.06.2008 Roswitha Kotthoff
changed 03.05.2018 Student Studienregister
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org